Improved functional JAG1 and NOTCH2 variant testing in patients with clinical or suspected Alagille syndrome using new low-Notch activity cells
Human Genetics · 2026-12 · 145 (1)
DOI: 10.1007/s00439-026-02832-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Genetics, online erschienen am 18.04.2026. Verfasst von Nicole Buhl und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Alagille Syndrome, Jagged-1 Protein, Receptor, Notch2. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
The autosomal dominant multisystemic Alagille Syndrome (ALGS) is an important cause of pediatric cholestasis. ALGS is associated with pathogenic variants in JAGGED1 (JAG1) or NOTCH2, ligand and receptor components of the Notch-signaling pathway, respectively. The detected missense variants are commonly classified as variants of uncertain significance, hindering ALGS diagnosis. To overcome this issue, we have developed a CRISPR/Cas9-engineered Low-Notch activity (LNA) cells allowing for selective testing of JAG1-NOTCH2 signaling activity. We tested this approach on 9 patients with pediatric hepatopathies with phenotypes ranging from the full clinical ALGS spectrum to isolated neonatal cholestasis and atypical ALGS abnormalities who carried 5 JAG1 and 3 NOTCH2 missense variants of interest. Additionally, western blot analyses revealed an effect on protein expression for two JAG1 missense variants, one of which had altered glycosylation, potentially indicating pathogenic effects. For this JAG1 and one NOTCH2 de novo missense variant, luciferase-based Notch reporter activity was significantly reduced in LNA cells, while no change was observed in commonly used HEK293T, Huh7, or Hep2G cells. These findings allow independent confirmation of recently classified c.53T>G p.(Leu18Arg) in JAG1 , and a re-classification of c.1235G>T p.(Cys412Phe) in NOTCH2 as likely pathogenic based on ACMG criteria. Collectively, we provide evidence that selective testing of JAG1-NOTCH2 interaction in the newly developed CRISPR-engineered cells, combined with a glycosylation assay, enables robust functional evaluation of ALGS-associated JAG1 and NOTCH2 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany.
- Department of Cell Biology, Faculty of Science, Charles University, Viničná 7, Prague, 12800, Czech Republic.
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
- Department of Human Genetics, Hannover Medical School, Carl- Neuberg-Str.1, 30625, Hannover, Germany.
- Hannover Unified Bank, Hannover Medical School, Hannover, Germany.
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Buhl, N., Pfister, E. D., Oliveira, D. V., Turetti, F., Lurz, E., Baumann, U., Di Donato, N., Illig, T., Skawran, B., Andersson, E. R., Mašek, J., & Stalke, A. (2026). Improved functional JAG1 and NOTCH2 variant testing in patients with clinical or suspected Alagille syndrome using new low-Notch activity cells. Human Genetics, 145(1). https://doi.org/10.1007/s00439-026-02832-7
Vancouver
Buhl N, Pfister ED, Oliveira DV, Turetti F, Lurz E, Baumann U, et al. Improved functional JAG1 and NOTCH2 variant testing in patients with clinical or suspected Alagille syndrome using new low-Notch activity cells. Human Genetics. 2026;145(1). doi:10.1007/s00439-026-02832-7
BibTeX
@article{Buhl2026,
author = {Buhl, Nicole and Pfister, Eva-Doreen and Oliveira, Daniel V and Turetti, Fabio and Lurz, Eberhard and Baumann, Ulrich and Di Donato, Nataliya and Illig, Thomas and Skawran, Britta and Andersson, Emma R and Mašek, Jan and Stalke, Amelie},
title = {Improved functional JAG1 and NOTCH2 variant testing in patients with clinical or suspected Alagille syndrome using new low-Notch activity cells},
journal = {Human Genetics},
year = {2026},
volume = {145},
number = {1},
doi = {10.1007/s00439-026-02832-7}
}
EUVIMED